Mixed chimerism and split tolerance: mechanisms and clinical correlations.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 3321885)

Published in Chimerism on April 17, 2012


David P Al-Adra1, Colin C Anderson

Author Affiliations

1: Department of Surgery, Alberta Diabetes Institute, University of Alberta, Edmonton, AB Canada.

Articles cited by this

(truncated to the top 100)

Actively acquired tolerance of foreign cells. Nature (1953) 19.82

Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2004) 13.79


Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

On the thymus in the differentiation of "H-2 self-recognition" by T cells: evidence for dual recognition? J Exp Med (1978) 9.51

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08

Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76

Genes and antibodies. Science (1959) 5.63

Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu (1980) 5.03

A simple method for inducing tolerance of skin homografts in mice. Transplant Bull (1957) 4.73

Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature (1984) 4.26

Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12

Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med (2008) 4.04

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Subspecific origin and haplotype diversity in the laboratory mouse. Nat Genet (2011) 3.64

Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34

Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med (1989) 3.34

Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med (2007) 3.22

Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18

Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol (1977) 3.13

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Continued maturation of thymic emigrants in the periphery. Nat Immunol (2004) 3.08

First human face allograft: early report. Lancet (2006) 3.01

Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. Surg Forum (1969) 2.80

Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science (2007) 2.69

Does T-cell tolerance require a dedicated antigen-presenting cell? Nature (1989) 2.41

Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell (2011) 2.35

Tissue-based class control: the other side of tolerance. Nat Rev Immunol (2011) 2.33

Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation (1991) 2.32

Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol (2002) 2.25

Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med (2000) 2.16

Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation (1999) 2.16

Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst (1955) 2.16

Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol (1999) 2.13

Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes (2005) 2.10

Induced immune tolerance for kidney transplantation. N Engl J Med (2011) 2.08

Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med (1985) 2.00

Rejection of skin allografts by radiation chimaeras: selective gene action in the specification of cell surface structure. Nature (1970) 1.95

Immunity or tolerance: opposite outcomes of microchimerism from skin grafts. Nat Med (2001) 1.93

The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S A (1993) 1.86

Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery (1976) 1.84

Human embryonic stem cells possess immune-privileged properties. Stem Cells (2004) 1.82

Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol (1994) 1.77

Minor but not major histocompatibility antigens of thymus epithelium tolerize precursors of cytolytic T cells. Nature (1986) 1.69

Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation (1999) 1.66

Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med (1998) 1.65

Microchimerism is strongly correlated with tolerance to noninherited maternal antigens in mice. Blood (2009) 1.63

Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood (1999) 1.63

Niche recycling through division-independent egress of hematopoietic stem cells. J Exp Med (2009) 1.62

CD8 T cells can reject major histocompatibility complex class I-deficient skin allografts. Am J Transplant (2004) 1.57

The thymus and negative selection. Immunol Rev (2002) 1.52

Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med (1992) 1.46

Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol (2001) 1.46

Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation (1997) 1.45

The non-obese diabetic (NOD) mouse. Am J Pathol (1987) 1.40

The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. Nat Med (1999) 1.35

Two levels of help for B cell alloantibody production. J Exp Med (1996) 1.31

Whither T-suppressors: if they didn't exist would we have to invent them? Cell Immunol (2004) 1.27

Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol (1998) 1.26

Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells. Blood (2004) 1.26

Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation (1998) 1.25

Patterns of donor-type microchimerism after heart transplantation. Lancet (1994) 1.25

Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg (1999) 1.24

Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med (1994) 1.24

Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc (1970) 1.22

Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology (1998) 1.21

Differential survival of skin and heart allografts in radiation chimaeras provides further evidence for Sk histocompatibility antigen. Nature (1974) 1.20

Fetal cells in the pregnant mouse are diverse and express a variety of progenitor and differentiated cell markers. Biol Reprod (2009) 1.20

Combined kidney/bone marrow transplantation--evidence of augmentation of chimerism. Transplantation (1995) 1.19

Cutting edge: Contact with secondary lymphoid organs drives postthymic T cell maturation. J Immunol (2008) 1.18

Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance. Transplantation (1996) 1.18

Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant (2011) 1.17

Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes (2003) 1.17

The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant (2005) 1.16

Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J Immunol (2001) 1.16

Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. Transplantation (1994) 1.16

Donor-type microchimerism associated with graft rejection eight years after liver transplantation. N Engl J Med (1994) 1.13

Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation (2011) 1.12

The balance of deletion and regulation in allograft tolerance. Immunol Rev (2003) 1.11

The male minor transplantation antigen preferentially activates recipient CD4+ T cells through the indirect presentation pathway in vivo. J Immunol (2003) 1.09

Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol. J Immunol (2005) 1.08

Development, stability, and clinical correlations of allogeneic microchimerism after solid organ transplantation. Transplantation (1996) 1.08

NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes (2003) 1.05

The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci U S A (1991) 1.05

Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood (2001) 1.04

Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation (1996) 1.03

Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation (2001) 1.03

Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation. Am J Transplant (2009) 1.02

Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proc Natl Acad Sci U S A (2007) 1.02

Combined bone marrow and whole organ transplantation from the same donor. Transplant Proc (1994) 1.02

Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection. Nat Med (1998) 1.01

Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol (2003) 1.00

Acute rejection in the absence of cognate recognition of allograft by T cells. J Immunol (2001) 1.00

Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J Immunol (1996) 1.00

Combined simultaneous kidney/bone marrow transplantation. Transplantation (1995) 0.98

Partial donor-specific tolerance to delayed skin grafts after rejection of hematopoietic cell graft. Transplantation (2006) 0.97

Thymic cortical epithelium induces self tolerance. Eur J Immunol (2005) 0.95

The ability of natural tolerance to be applied to allogeneic tissue: determinants and limits. Biol Direct (2007) 0.95

Articles by these authors

CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood (2007) 2.68

BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol (2009) 1.53

Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes (2006) 1.05

Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant (2004) 1.00

Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int (2008) 1.00

Development of either split tolerance or robust tolerance along with humoral tolerance to donor and third-party alloantigens in nonmyeloablative mixed chimeras. J Immunol (2008) 0.95

The ability of natural tolerance to be applied to allogeneic tissue: determinants and limits. Biol Direct (2007) 0.95

Thymic cortical epithelium induces self tolerance. Eur J Immunol (2005) 0.95

Decellularization reduces the immune response to aortic valve allografts in the rat. J Thorac Cardiovasc Surg (2005) 0.95

Coinhibitory T-cell signaling in islet allograft rejection and tolerance. Cell Transplant (2006) 0.92

Non-myeloablative mixed chimerism approaches and tolerance, a split decision. Eur J Immunol (2007) 0.88

Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning. Transplantation (2005) 0.86

A nude mouse model of hypertrophic scar shows morphologic and histologic characteristics of human hypertrophic scar. Wound Repair Regen (2012) 0.84

Differential susceptibility of allogeneic targets to indirect CD4 immunity generates split tolerance. J Immunol (2008) 0.83

The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants. Immunobiology (2011) 0.82

Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival. Transplantation (2007) 0.81

Compaction of islets is detrimental to transplant outcome in mice. Transplantation (2006) 0.80

Chemokines and their receptors in islet allograft rejection and as targets for tolerance induction. Cell Transplant (2006) 0.80

Protein kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats. Transplantation (2009) 0.79

Co-inhibitory molecules: Controlling the effectors or controlling the controllers? Self Nonself (2010) 0.78

Control of in vivo collateral damage generated by T cell immunity. J Immunol (2013) 0.78

PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells. Eur J Immunol (2014) 0.77

Soluble donor DNA and islet injury after transplantation. Transplantation (2011) 0.76

Toward minimal conditioning protocols for allogeneic chimerism in tolerance resistant recipients. Chimerism (2013) 0.75

A discussion of immune tolerance and the layered immune system hypothesis. Chimerism (2013) 0.75

Comment on: Ten experiments that would make a difference in understanding immune mechanisms. Cell Mol Life Sci (2011) 0.75

Nonobese diabetic natural killer cells: a barrier to allogeneic chimerism that can be reduced by rapamycin. Transplantation (2011) 0.75

Divide and conquer: Blocking graft versus host but not graft versus leukemia T cells with agonist BTLA co-inhibitory signals. Chimerism (2011) 0.75

T cells generated in the absence of a thoracic thymus fail to establish homeostasis. Eur J Immunol (2014) 0.75

Morphologic and Histologic Comparison of Hypertrophic Scar in Nude Mice, T-Cell Receptor, and Recombination Activating Gene Knockout Mice. Plast Reconstr Surg (2015) 0.75

An essential role for programmed death-1 in the control of autoimmunity: implications for the future of hematopoietic stem cell transplantation. Future Oncol (2011) 0.75